Physician profile
Jeffrey Eckman
NPI 1760482376
$10,467.63
in general payments reported to CMS, 2019-2025
43 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $2,159 · 2021: $2,277 · 2022: $1,974 · 2023: $706 · 2024: $724 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,412.56 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,119.53 | 2019-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $1,108.74 | 2019-2025 | |
| Amgen INC. | $1,018.67 | 2019-2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $918.58 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $738.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $680.12 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $513.02 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.12 | 2019-2025 | Jardiance, Spiriva Respimat |
| Amarin Pharma, INC. | $278.10 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $250.51 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $235.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $197.91 | 2019-2023 | Ponvory |
| Radius Health, INC. | $171.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $158.58 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Eckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.